| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Cash paid for financing costs in connection with sepa | - | 297,783 |
| Proceeds from stock options exercised | 162,400 | - |
| Represent the amount of proceeds from issuance of common shares and warrants | - | 9,790,015 |
| Costs to issue debentures | 136,726 | - |
| Represents the amount of proceed from costs to issue debentures | - | -54,582 |
| Issuance costs for common shares | 584,361 | - |
| Net cash provided by financing activities | 25,286,315 | 14,915,048 |
| Represents the amount of net cash paid for antev asset acquisition including transaction costs | 4,619,152 | - |
| Cash provided by (used in) investing activity, including discontinued operation | -4,619,152 | - |
| Effect of exchange rate on cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation | -1,741 | - |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation | 4,497,768 | - |
| Cash and cash equivalents at beginning of period | 4,164,323 | - |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents, period increase (decrease), excluding exchange rate effect | - | 5,505,223 |
| Cash and cash equivalents at end of period | 8,662,091 | - |
Medicus Pharma Ltd. (MDCX)
Medicus Pharma Ltd. (MDCX)